The cellular and molecular basis of prostate cancer

BJU International

Volumn 83, Issue 2, 1999, Pages 171-194

  Foster, C S ^a   Cornford, P ^a   Forsyth, L ^a   Djamgoz, M B A ^b   Ke, Y ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; GENE PRODUCT; GROWTH FACTOR; HORMONE; OSTEOPONTIN; POTASSIUM CHANNEL; PROTEIN; PROTEIN BCL 2; SODIUM CHANNEL;

APOPTOSIS; CELL KINETICS; CELL PROLIFERATION; HUMAN; MALE; MOLECULAR GENETICS; NEOPLASM; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CARCINOMA IN SITU; CELL ADHESION MOLECULES; CELL DIVISION; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; ION CHANNELS; MALE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SECOND MESSENGER SYSTEMS;

EID: 0038572216     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00954.x     Document Type: Review

References (204)

1. 1 Foster CS. Predictive factors in prostatic hyperplasia and neoplasia. Hum Pathol 1990; 21: 575-7
2. 2 Foster CS, Abel PD. Clinical and molecular techniques for diagnosis and monitoring of prostatic cancer. Hum Pathol 1992; 23: 395-401
3. 3 Bostwick DG, Drawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788-94
4. 4 Bostwick DG. Progression of prostatic intraepithelial neoplasia lo early invasive adenocarcinoma. Eur Urol 1996; 30: 145-52
5. 5 Lee F, Torp-Pedersen ST, Caroll JT, Siders DB, Christensen-Day C, Mitchell AE. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia. Urology 1989; 34: 4-8
6. 6 Davidson D, Bostwick DG, Qian JQ et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: Predictive accuracy in needle biopsies. J Urol 1995; 154: 1295-9
7. 7 Markham CW. Prostatic intraepithelial neoplasia -detection and correlation with invasive cancer in fine-needle biopsy. Urology 1989; 34: 57-61
8. 8 Park C, Galang C, Johenning P, Maksem J, Tannenbaum M. Follow-up aspiration biopsies for dysplasia of the prostate gland. Lab Invest 1989; 60: 70A
9. 9 Brawer MK, Bigler SA, Sohlberg OE, Nagle RB, Lange PH. Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 1991; 38: 103-7
10. 10 Berner A, Danielsen HE, Pettersen EO, Fossa SD, Reith A, Nesland JM. DNA distribution in the prostate: Normal gland, benign and premalignant lesions and subsequent adenocarcinomas. Anal Quant Cytol Histol 1993; 15: 247-52
11. 11 Weinstein MH, Epstein JI. Significance of high grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24: 624-9
12. 12 Bostwick DG, Qian JQ, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995; 154: 1791-4
13. 13 Keetch DW, Humphrey P, Stahl D, Smith DS, Catelona WJ. Morphometric analysis and clinical follow-up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995; 154: 347-51
14. 14 Allsbrook WC, Pfeiffer EA. Histochemistry of the prostate. In Foster CS, Bostwick DG, eds. Pathology of the Prostate. Philadelphia: WB Saunders, 1997: 282-303
15. 15 Shih C, Shilo B, Goldford MP, Dannenberg S, Weinberg RA. Passage of phenotypes of chemically transformed cells via transfcction of DNA and chromatin. Proc Nat Acad Sci USA 1979; 76: 5714-8
16. 16 Viola MV, Fromwitz F, Oravez S et al. Expression of ras oncogene p21 in prostate cancer. New Eng J Med 1986; 314: 133-7
17. 17 Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 1987; 10: 281-9
18. 18 Carter BS, Epstein JI, Isaacs WB. ras Gene mutations in human prostate cancer. Cancer Res 1990; 50: 6830-2
19. 19 Fan K. Heterogeneous subpopulations of human prostatic adenocarcinoma cells. Potential usefulness of P21 protein as a predictor of bone metastasis. J Urol 1988; 159: 318-22
20. 20 Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 1988; 13: 263-72
21. 21 Vocke CD, Pozzatti RO, Bostwick DG et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996; 56: 2411-6
22. 22 Sanchez Y, Lovell M, Marin MC et al. Tumor suppression and apoptosis of human prostate carcinoma mediated by a genetic locus with human chromosome 10pter-q11. Proc Nat Acad Sci USA 1996; 93: 2551-6
23. 23 Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996; 56: 1142-5
24. 24 MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996; 35: 55-65
25. 25 Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 1996; 35: 46-54
26. 26 Kunimi K, Amano T, Uchibayashi T. Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect Prev 1996; 20: 218-22
27. 27 Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996; 56: 4150-3
28. 28 Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL. Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 1996; 56: 2157-60
29. 29 Ittmann MM. Loss of heterozygosity on chromosome 10 and 17 in clinically localized prostate carcinoma. Prostate 1996; 28: 275-81
30. 30 Williams BJ, Jones E, Zhu XL et al. Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 1996; 155: 720-5
31. 31 Gao X, Zacharek A, Grignon DJ et al. Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 1995; 11: 1241-7
32. 32 Kagan J, Stein J, Babaian RJ et al. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 1995; 16: 2121-6
33. 33 Macoska JA, Trybus TM, Benson PD et al. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995; 55: 5390-5
34. 34 Gray IC, Phillips SMA, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995; 55: 4800-3
35. 35 Komiya A, Suzuki H, Aida S. Yatani R, Shimazaki J. Mutational analysis of CDKN2 (CDK41/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 1995; 86: 622-5
36. 36 Herman JG, Merlo A, Mao L et al. Inactivation of the CDKN2/p 16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30
37. 37 Cairns P, Polascik TJ, Eby Y et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995; 11: 210-2
38. 38 Suzuki H, Emi M, Komiya A et al. Localization of a tumor suppressor gene associated with progression of human prostate cancer with a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995; 13: 168-74
39. 39 Murakami YS, Brothman AR, Leach RJ, While RL. Suppression of malignant phenotype in a human prostate cancer cell-line by fragments of normal chromosomal region 17q. Cancer Res 1995; 55: 3389-94
40. 40 Emmert-Buck MR, Vocke CD, Pozzatti RO et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995; 55: 2959-62
41. 41 Eagle LR, Yin XY, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MX11 gene in prostate cancer. Nat Genet 1995; 9: 249-55
42. 42 Dong JT, Lamb PW, Rinker-Schaeffer CW et al. KAI 1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884-6
43. 43 Gao X, Zacharek A, Salkowski A et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995; 55: 1002-5
44. 44 MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Gene Chrom Cancer 1994; 10: 151-9
45. 45 Trapman J, Sleddens HF, van der Weiden MM et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994; 54: 6061-4
46. 46 Burney TL, Rockove S, Eiseman JL, Jacobs SC, Kyprianou N. Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. Prostate 1994; 25: 177-88
47. 47 Berube NG, Speevak MD, Chevrette M. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del (12) (q13). Cancer Res 1994; 54: 3077-81
48. 48 Stanbridge EJA. Human tumor suppressor genes. Annu Rev Gen 1990; 24: 615-57
49. 49 Yunis JJ, Ramsay N. Retinoblasloma and subband deletion of chromosome 13. Am J Dis Child 1978; 132: 161-3
50. 50 Friend SH, Bernards R, Rogelj S et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643-6
51. 51 Benedict WF, Xu HJ, Hu SX, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990; 85: 988-93
52. 52 Bookstein R, Rio P, Madreperla SA et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Nat Acad Sci USA 1990; 87: 7762-6
53. 53 Mercer WE, Avignolo C, Baserga R. Role of the p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 1984; 4: 276-81
54. 54 Levine AJ, Momand J. Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1990; 1032: 119-36
55. 55 Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc 70-p53 complex with an altered half life. Mol Cell Biol 1988; 8: 531-9
56. 56 Rotter V, Abutbul H, Ben-Ze'ev A. p53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J 1983; 2: 1041-7
57. 57 Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739-46
58. 58 Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93
59. 59 Foster CS, McLoughlin J, Bashir I, Abel PD. Markers of the metastatic phenotype in prostate cancer. Hum Pathol 1992; 23: 381-94
60. 60 Mottaz AE, Markwalder R, Fey MF et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. The Prostate 1997; 31: 209-15
61. 61 Sharon N, Lis H. Lectins as cell recognition molecules. Science 1989; 246: 227-34
62. 62 Foster CS. Functional aspects of glycoprotein N-linked oligosaceharide processing by human tumors. Br J Cancer 1990; 62: 57-63
63. 63 Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 1992; 168: 7-13
64. 64 Visakorpi T, Kallionemi O-P, Paronen IYI et al. Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer 1991; 64: 578-82
65. 65 Vesalainen SLB, Lipponen PK, Talja MT, Alhava EM, Syrjanen KJ. Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2MO prostatic adenocarcinoma. Int J Cancer 1994; 58: 303-8
66. 66 Ogata K, Kurki P, Celis JE, Nakamura RM, Tan EM. Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp Cell Res 1988; 168: 475-86
67. 67 Waseem NH, Lane DP. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 1990; 96: 121-9
68. 68 Dawson AE, Norton JA, Weinberg DS. Comparative-assessment of proliferation and DNA content in breast carcinoma by image-analysis and flow cytometry.
69. 69 Landberg G, Roos G. Antibodies to proliferating cell nuclear antigen as S-phase probes in flow cytometric cell cycle analysis. Cancer Res 1991; 51: 4570-4
70. 70 Gerdes J, Schwab U, Lemke H, Stein H. The production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20
71. 71 Verheijen R, Kuijpers HJH, Schlingemann RO et al. Ki67 detects a nuclear matrix associated proliferation related antigen 1. Intracellular localization during interphase. J Cell Sci 1989; 92: 123-30
72. 72 Verheijen R, Kuijpers HJH, Vandriel R. et al. Ki67 detects a nuclear matrix associated proliferation related antigen. II. Localisation in mitotic cells and association with chromosomes. J Cell Sci 1989; 92: 531-40
73. 73 van Dierendonck JH, Keijzer R, van de Velde CJH, Cornelisse CJ. Nuclear distribution of the Ki67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 1989; 49: 2999-3006
74. 74 Schluter C, Duchrow M, Wohlenberg C et al. The cell proliferation associated antigen of antibody Ki67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining protein. J Cell Biol 1993; 123: 513-22
75. 75 Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki67 antibody in HL-60 cells. Cell Proliferation 1992; 25: 31-40
76. 76 Ross W, Hall PA. Ki67 from antibody to molecule to understanding? J Clin Pathol: Mol Pathol 1995; 48: M113-7
77. 77 Hall PA, Levison DA. Assessment of cell-proliferation in histological material. J Clin Pathol 1990; 43: 184-92
78. 78 Bubendorf L, Sauter G, Moch H et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437-41
79. 79 Harper ME, Goddard L, Wilson DW et al. Pathological and clinical associations of Ki67 defined growth fractions in human prostatic carcinoma. Prostate 1992; 21: 75-84
80. 80 Krishna M, Khan A, Woda B, Menon M, Malhotra R. Expression and prognostic significance of p53, Ki67, c-erbB2 in prostate carcinoma. Lab Invest 1995; 72: A79
81. 81 Cher ML, Chew K, Rosenau W, Carroll PR. Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67, and PCNA expression. Prostate 1995; 26: 87-93
82. 82 Tang DG, Porter AT. Target to apoptosis: a hopeful weapon for prostate cancer. Prostate 1997; 32: 284-93
83. 83 Isaacs JT, Lundmo PI, Berges R et al. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992; 13: 457-64
84. 84 Montpetit ML, Lawless KR, Tenniswood M. Androgen repressed messages in the rat ventral prostate. Prostate 1986; 8: 25-36
85. 85 Kyprianou N, Isaacs J. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Molec Endocrinol 1989; 3: 1515-22
86. 86 Montironi R, Diamanti L. Morphological changes in benign prostatic hyperplasia following chronic treatment with 5-alpha-reductase inhibitor Finasteride; Comparison with the effect of combination endocrine therapy. J Urol Pathol 1996; 4: 123-35
87. 87 Civantos F, Watson RB, Edson-Pinto J, Korman HJ, Soloway MS. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997; 6: 1-13
88. 88 Kim IY, Ahn HJ, Zeiner DJ et al. Genetic change in transforming growth factor (TGFbeta) receptor type I gene correlates with insensitivity to TGF-beta1 in human prostate cancer cells. Cancer Res 1996; 56: 44-8
89. 89aLu Q-L Abel P, Foster CS, Lalani E-M. bcl-2: role in epithelial differentiation and oncogenesis. Human Pathology 1996; 27: 102-110
90. 89 Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62
91. 90 Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6
92. 91 Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 1996; 88: 386-401
93. 92 Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Haem Oncol Clin North Am 1995; 9: 451-75
94. 93 Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994; 79: 189-92
95. 94 Krajewski S, Krajewska M, Shabaik A et al. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994; 145: 1323-36
96. 95 Krajewski S, Krajewska M. Immunohistochemical analysis of in vivo patterns of Bcl-x expression. Cancer Res 1994; 54: 5501-7
97. 96 Krajewski S, Bodrug S, Krajewska M et al. Immunohistochemical analysis of Mcl-1 protein in human tissues: differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995; 146: 1309-19
98. 97 Shabaik AS, Krajewski S, Burgan A, Krajewska M, Reed JC. Bcl-2 proto-oncogene expression in normal, hyperplastic and neoplastic prostate tissue. Lab Invest 1994; 70: A83
99. 98 Merlo GR, Cella N, Hynes NE. Apoptosis is accompanied by changes in Bcl-2 and Bax Expression, induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells. Cell Growth Diff 1997; 8: 251-60
100. 99 Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-4
101. 100 Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-805
102. 101 Minn AJ, Velez P, Schendel SL et al. Bcl-x (L) forms an ion channel in synthetic lipid membranes. Nature 1997; 385: 353-7
103. 102 Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3: 614-20
104. 103 Moul JW, Bettencourt MC, Sesterhenn IA et al. Protein expression of p53, bcl-2 and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996; 120: 159-67
105. 104 Colombel M, Symmans F, Gil S et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993; 143: 390-400
106. 105 McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996; 56: 5594-9
107. 106 Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995; 55: 4438-45
108. 107 Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253-5
109. 108 Livingstone LR, White A. Sprouse J. et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-35
110. 109 Vaux D, Cory S, Adams J. Bcl-gene promotes hematopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-2
111. 110 Kerr JFR, Winterford CM, Harmon BV. Apoptosis - its significance in cancer and cancer therapy. Cancer 1994; 73: 2013-26
112. 111 Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-39
113. 112 McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4
114. 113 Berchem GJ, Bosseler M, Sugars LY et al. Androgens induce resistance to bcl-2 mediated apoptosis in LNCap prostate cancer cells. Cancer Res 1995; 55: 735-8
115. 114 Lipponen P, Vesalainen S. Expression of the apoptosis suppressing protein bcl-2 in prostatic adenocarcinoma is related to tumour malignancy. The Prostate 1997; 32: 9-15
116. 115 Krajewska M, Krajewski S, Epstein JI et al. Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76
117. 116 Berges RR, Furuya Y, Remington L et al. Cell proliferation, DNA repair and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Nat Acad Sci USA 1993; 90: 910-4
118. 117 Borner MM, Myers CE, Sartor O et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis of proliferation in the p53-negative human prostate cancer cell line PC3. Cancer Res 1995; 55: 2122-8
119. 118 Vulkanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55: 1499-504
120. 119 Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res 1995; 55: 3712-5
121. 120 Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA. Beta-lapachone-mediated apoptosis in human promyelocytic leukaemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res 1995; 55: 3706-11
122. 121 Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing reception CD44 reveals at least 12 alternatively spliced exons. Proc Nat Acad Sci 1992; 89: 12160-4
123. 122 Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124: 71-82
124. 123 Prins GS, Birch L. Neonatal estrogen exposure up-regulates estrogen receptor expression in the developing and adult rat prostate lobes. Endocrinology 1997; 138: 1801-9
125. 124 Kruithof-Dekker IG, Tetu B, Janssen PJ, Van Der Kwast TH. Elevated estrogen receptor expression in human prostatic stromal cells by androgen ablation therapy. J Urol 1996; 156: 1194-7
126. 125 Wakefield LM, Thompson NL, Flanders KC, O'Connor-M, Court MD, Sporn MB. Transforming growth factor-beta: Multifunctional regulator of cell growth and phenotype. Ann N Y Acad Sci 1988; 551: 290-8
127. 126 Massague J. The transforming growth factor-beta family. Ann Rev Cell Biol 1990; 6: 597-641
128. 127 Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: New mechanistic insighls. Cell 1990; 63: 245-7
129. 128 Merz VW, Arnold AM, Studer UE. Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-Fos mRMA in normal human prostate, benign prostatic hyperplasia, and prostatic cancer. World J Urol 1994; 12: 96-8
130. 129 Kim SJ, Park K, Koeller D et al. Post-transcriptional regulation of human transforming growth factor-beta 1 gene. J Biol Chem 1992; 267: 13702-7
131. 130 Perry KT, Anthony CT, Steiner MS. Immunohistochemical localization of TCP-beta 1, TGF-beta 2, and TGF-beta 3 in normal and malignant human prostate. The Prostate 1997; 33: 133-40
132. 131 Steiner MS. Transforming growth factor-beta and prostate cancer. World J Urol 1995; 13: 329-36
133. 132 McKeehan WL, Adums PS. Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta in vitro. Cell Dev Biol 1988; 24: 243-6
134. 133 Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells. Endocrinology 1990; 127: 2963-8
135. 134 Sutowski DM, Fong CJ, Sensibar JA et al. Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Prostate 1992; 21: 133-43
136. 135 Charpin C, Garcia S, Bouvier C et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289-96
137. 136 Welsh CF, Zhu D, Bourguignon LYW. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995; 164: 605-12
138. 137 Arch R, Wirth K, Hofmann M et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257: 682-5
139. 138 Terpe HJ, Stark H, Prehm P, Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994; 101: 79-89
140. 139 Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumour growth in vivo. J Exp Med 1991: 174: 859-66
141. 140 Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cells 1991; 65: 13-24
142. 141 Rudy W, Hofmann R, Schwartz-Albiez R et al. Two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res 1993; 53: 1262-8
143. 142 Seiter S, Arch R, Reber S et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443-55
144. 143 Fox SB, Fawcett J, Jackson DG et al. Normal human tissues in addition to some tumours, express multiple different CD44 isoforms. Cancer Res 1994; 54: 4539-46
145. 144 Pretlow TG, Nagabhushan M, Sy M, Guo YJ, Pretlow TP. Putative preneoplastic foci in the human prostate. J Cell Riochem 1994; 19: 224-31
146. 145 Dhir R, Evans BA, Hakam A, Bahnson RR, Cooper DL, Becich MJ. Immunohistochemical detection of standard and variant forms of CD44 in normal and neoplastic prostates. Am J Clin Pathol 1995; 104: 344-5
147. 146 Liu AY. Expression of CD44 in prostate cancer cells. Cancer Lett 1994; 76: 63-9
148. 147 Stevens JW, Palecheck PL, Griebling TL, Midura RJ, Rokhlin OW, Cohen MB. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate 1996; 28: 153-61
149. 148 Iczkowski KA, Pantazis CG, Collins J. The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol 1997; 6: 119-29
150. 149 Gelb A, Gakunga P, Shuster S, Stern R. Profile of CD44 expression in prostatic carcinoma: a potential marker for tumor aggressiveness. Modern Pathol 1977; 10: 76A
151. 150 Foster CS, Cornford P, Ke Y, Djamgoz M. New aspects of prostate cancer metastasis. Virchows Archiv 1999; in press
152. 151 Nomura S, Willis AJ, Edwards DR, Heath JK, Hogan BLM. Developmental expression of 2ar (osteopontin) and SPARC losteonectinl RNA as revealed by in situ hybridization. J Cell Biol 1988; 106: 441-50
153. 152 Brown LF, Berse B, Van De Water L et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Cell Biol 1992; 3: 1169-80
154. 153 Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Nat Acad Sci USA 1986; 83: 8819-23
155. 154 Ross FP, Chappell J, Alvarez JI et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha-v-beta-3 potentiate bone resorption. J Biol Chem 1993; 268: 9901-7
156. 155 Brown LF, Papadopousos-Sergiou A, Berse B et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23
157. 156 Pongracz J, Johnson GD, Crocker J, Burnett D, Lord JM. The role of protein kinase C in myeloid cell apoptosis. Biochem Soc Trans 1994; 22: 593-7
158. 157 Evans JD, Bramhall SR, Neoptolemos JP, Eggo ME. Mechanisms of apoptosis in pancreatic cancer cell lines. Br J Surg 1996; 83: 1631
159. 158 Mohammad RM, Diwakaran H, Maki A et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 1995; 19: 667-73
160. 159 Lord JM, Pongracz J. Protein kinase C: a family of isoenzymes with distinct roles in pathogenesis. J Clin Pathol: Mol Pathol 1995; 48: 57-64
161. 160 Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (k562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for proliferation. J Biol Chem 1993; 268: 15847-53
162. 161 MacFarlane DE, Manzel L. Activation of beta-isoenzyme of protein kinase C (PKC beta) is necessary and sufficient for phorbol ester-induced differentiation of HL60 promyelocytes. Studies with PCK-beta defective PET mutant. J Biol Chem 1994; 269: 4327-31
163. 162 Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993; 8: 2095-104
164. 163 Powell CT, Fair WR, Heston WD. Differential expression of protein kinase C isoenzymes messenger RNAs in Dunning R-3327 rat prostatic tumours. Cell Growth Diff 1994; 5: 143-9
165. 164 Sosnowski J, Stetter-Neel C, Cole D, Durham JP, Mawhinney MG. Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumour cells. J Urol 1997; 158: 269-74
166. 165 Rusnak JM, Lazo JS. Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp Cell Res 1996; 224: 189-99
167. 166 Lee YJ, Berns CM, Erdos G, Corry PM. Effect of isoquinoline-sulfonamides on heal shock gene expression during heating at 41 degree C in human carcinoma cell lines. Biochem Biophys Res Com 1994; 199: 714-9
168. 167 Cooper GM, Okenquist S, Silverman L. Transforming activity of DNA of chemically transformed and normal cells. Nature 1980; 284: 181-8
169. 168 Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261-4
170. 169 Krontiris TG, Cooper GM. Transforming activity of human-tumor DNAs. Proc Nat Acad Sci 1981; 78: 1181-4
171. 170 Hall A, Marshall CJ, Spurr NK, Weiss RA. Identification of transforming gene in two human sarcoma cell-lines as a new member of the RAS gene family located on chromosome 1. Nature 1983; 303: 396-400
172. 171 Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least 2 cooperating oncogenes. Nature 1983; 304; 596-602
173. 172 Hayle AJ, Darling DL, Taylor AR, Train D. Transaction of metastatic capability with total genomic DNA from human and mouse metastatic tumor cell-lines. Differentiation 1993; 54: 177-89
174. 173 Cate CC, Belloni DR, Marin-Padilla M. Acquisition and enhanced expression of the metastatic phenotype following transactions of genomic mouse tumor DNA containing human SCLC gene sequences. Clin Exp Met 1995; 13: 203-17
175. 174 Chen H, Ke Y, Oates AO, Barraclough R, Rudland PS. Isolation of and the effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14: 1581-8
176. 175 Ke Y, Beesley C, Smith P, Barraclough R, Rudland P, Foster CS. Generation of metastatic variants by transfection of a rat nonmetastatic epithelial cell-line with genomic DNA from rat prostatic carcinoma cells. Br J Cancer 1998; 77: 287-96
177. 176 Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967-71
178. 177 Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res 1991; 51: 3788-92
179. 178 Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-4
180. 179 Davies BR, Barraclough R, Rudland PS. Induction of metastatic ability in a stably diploid benign rat mammary epithelial cell line by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 1994; 54: 2785-93
181. 180 Ke Y, Jing C, Barraclough R, Smith P, Davies MPA. Foster CS. Elevated expression of calcium-binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma ceils. Int J Cancer 1997; 71: 832-7
182. 181 Barraclough R, Savin J, Dube SK, Rudland PS. Molecular cloning and sequence of the gene for p9Ka: a cultured myoepithelial cell protein with strong homology to S-100, A calcium-binding protein. J Mol Biol 1987; 198: 13-20
183. 182 Desplan C, Heidmann O, Lillie JW, Auffray C, Thomasset M. Sequence of rat intestinal vitamin D-dependent calcium-binding protein derived from cDNA clone evolutionary implications. J Biol Chem 1983; 258: 3502-5
184. 183 Kuwano R, Maeda T, Usui H et al. Molecular-cloning of cDNA of s100-alpha subunit messenger RNA. FEBS Lett 1986; 202: 97-101
185. 184 Calabretta B, Battini R, Kraczmarek L, Deriel JK, Baserga R. Molecular-cloning of the cDNA for a growth factor-inducible gene with strong homology to s-100, a calcium-binding protein. J Biol Chem 1986; 261: 2628-32
186. 185 Gerke V, Weber K. The regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein-kinases is related in sequence to the S-100 protein of glial-cells. EMBO J 1985; 4: 2917-20
187. 186 Tufty RM, Kretsinger RH. Troponin and parvalbumin calcium-binding regions predicted in myosin light chain and T4 lysozyme. Science 1975; 187: 167-9
188. 187 Krestsinger RH, Tolbert D, Nakayama S, Pearson W. The EF-hand, homologs and analogs. In Novel Calcium-Binding Proteins: Fundamental and Clinical Implications. Vol 65, Berlin: Springer-Verlag, 1991: 17-37
189. 188 Gibbs FEM, Wilkinson MC, Rudland PS, Barraclough R. Interactions in vitro of p9Ka, the rat S-100 related, metastasis-inducing, calcium-binding protein. J Biol Chem 1994; 269: 18992-9
190. 189 Goebeler M, Roth J, Van Den Bos C, Ader G, Sorg C. Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J 1995; 309: 419-24
191. 190 Barraclough R, Gibbs F, Smith JA, Haynes GA, Rudland PS. Calcium ion-binding by the potential calcium ion-binding protein, p9Ka. Biochem Biophys Res Com 1990; 169: 660-6
192. 191 Pechere JF. Calcium-binding proteins und calcium function. Amsterdam: Elsevier, 1977
193. 192 Van Eldik LJ, Zendegui JG, Marshak OR, Watterson DM. Calcium-binding proteins and the molecular basis of calcium action. Int Rev Cytol 1982; 77: 1-61
194. 193 Hilt D, Kligman D. The S-100 Protein Family: a Biochemical and Functional Overview: In Novel Calcium-Binding Proteins: Fundamentals and Clinical Implications. Vol 65, Berlin: Springer-Verlag, 1991: 65-103
195. 194 Grimes JA, Fraser SP, Stephens GJ et al. Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: Contribution to invasiveness in vitro. FEBS Lett 1995; 369: 290-4
196. 195 Grimes JA, Djamgoz MBA. Electrophysiological characterization of voltage-gated Na+ current expressed in the highly metastatic Mat-LyLu cell line of rat prostate cancer. J Cell Physiol 1998; 175: 50-58
197. + channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 1997; 150: 1213-21
198. 197 Smith P, Rhodes NP, Shortland AP et al Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett 1998; 423: 19-24
199. + channel in rat and human prostate cancer cell lines. FEBS Letts 1998; 427: 5-10
200. 199 Skryma RN, Prevarskaya NB, Dufy-Barbe L, Odessa MF, Audin J, Dufy B. Potassium conductance in the androgen-sensitive prostate cancer cell line LNCaP: involvement in cell proliferation. The Prostate 1997; 33: 112-22
201. 200 Strobl JS, Wonderlin WF, Flynn DC. Mitogenic signal transduction in human breast cancer cells. Gen Pharmacol 1995; 26: 1643-9
202. 201 Caffrey JM, Brown AM, Hess P. Mitogens and oncogenes can block the iduction of specific voltage-gated ion channels. Science; 1987; 239: 570-3.
203. 202 Repp H, Braheim H, Ruland J et al. Profound differences in potassium current properties of normal and Rous sarcoma virus-transformed chicken embryo fibroblasts. Prac Natl Acad Sci USA 1993; 90: 3403-7.
204. 203 Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998; 83: 1180-8.